Lupin And Mylan Launch Etanercept in Germany

Germany First European Market For Nepexto

In partnership with Lupin, Mylan introduces Nepexto (etanercept) to the German market. After adalimumab, Nepexto is Mylan’s second immunology product in Germany.

Business People Shaking Hands With Flag of Germany
Lupin and Mylan partner to launch Nepexto in the German market • Source: Shutterstock

Lupin Limited and Mylan Pharmaceuticals Inc. have collaborated to launch Lupin’s biosimilar Nepexto (etanercept) in the German market. The partnership to bring Nepexto to Germany was announced shortly after the biosimilar was approved by the European Medicines Agency.

Thierry Volle, president for EMEA at Lupin, said, “Nepexto is our first biosimilar to receive regulatory approval in Europe.” He...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.